生命科学资讯

GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair

ARPA-H director eyes future beyond vaccines, ‘winning the biotech race’ against China

Abbott, AtaCor join forces on extravascular defibrillator implant

FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions

AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta

Immunology biotech Agomab, eye-focused SpyGlass are latest biotechs to share IPO ambitions

Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program

Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO

Chutes & Ladders—RFK Jr. continues overhaul of CDC vaccine panel

ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial

JPM26: Chugai chases new science and name recognition from US biopharma industry

JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears

Boston Scientific to snap up thrombectomy specialist Penumbra in deal valued at $14.5B

Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas

Novo Nordisk Foundation invests $860M in Danish institute nurturing homegrown biotechs

All the meetings, none of the megadeals: Is JPM's purpose evolving?

Italy's Alfasigma pens €125M deal for injectable form of German biotech's HSV treatment

Charles River inks $510M deal to bring primate supply in-house

JPM26: With pricing deal in the books, Sanofi steels against lingering policy unknowns

JPM26: Leo Pharma, hungry for more partnerships, looks to widen reach in rare dermatology diseases